Cargando…

Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy

Anti-idiotypic antibodies (anti-IDs) were discovered at the very beginning of the 20th century and have attracted attention of researchers for many years. Nowadays, there are five known types of anti-IDs: α, β, γ, ε, and δ. Due to the ability of internal-image anti-IDs to compete with an antigen for...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanova, Aliya K., Ryabkova, Varvara A., Tillib, Sergei V., Utekhin, Vladimir J., Churilov, Leonid P., Shoenfeld, Yehuda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345059/
https://www.ncbi.nlm.nih.gov/pubmed/32481667
http://dx.doi.org/10.3390/antib9020019
_version_ 1783556092692791296
author Stanova, Aliya K.
Ryabkova, Varvara A.
Tillib, Sergei V.
Utekhin, Vladimir J.
Churilov, Leonid P.
Shoenfeld, Yehuda
author_facet Stanova, Aliya K.
Ryabkova, Varvara A.
Tillib, Sergei V.
Utekhin, Vladimir J.
Churilov, Leonid P.
Shoenfeld, Yehuda
author_sort Stanova, Aliya K.
collection PubMed
description Anti-idiotypic antibodies (anti-IDs) were discovered at the very beginning of the 20th century and have attracted attention of researchers for many years. Nowadays, there are five known types of anti-IDs: α, β, γ, ε, and δ. Due to the ability of internal-image anti-IDs to compete with an antigen for binding to antibody and to alter the biologic activity of an antigen, anti-IDs have become a target in the search for new treatments of autoimmune illnesses, cancer, and some other diseases. In this review, we summarize the data about anti-IDs that mimic the structural and functional properties of some bioregulators (autacoids, neurotransmitters, hormones, xenobiotics, and drugs) and evaluate their possible medical applications. The immune system is potentially able to reproduce or at least alter the effects of any biologically active endogenous or exogenous immunogenic agent via the anti-idiotypic principle, and probably regulates a broad spectrum of cell functions in the body, being a kind of universal remedy or immunacea, by analogy to the legendary ancient goddess of universal healing Panacea (Πανάκεια, Panakeia in Greek) in the treatment and prevention of diseases, possibly including non-infectious somatic and even hereditary ones.
format Online
Article
Text
id pubmed-7345059
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73450592020-07-09 Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy Stanova, Aliya K. Ryabkova, Varvara A. Tillib, Sergei V. Utekhin, Vladimir J. Churilov, Leonid P. Shoenfeld, Yehuda Antibodies (Basel) Review Anti-idiotypic antibodies (anti-IDs) were discovered at the very beginning of the 20th century and have attracted attention of researchers for many years. Nowadays, there are five known types of anti-IDs: α, β, γ, ε, and δ. Due to the ability of internal-image anti-IDs to compete with an antigen for binding to antibody and to alter the biologic activity of an antigen, anti-IDs have become a target in the search for new treatments of autoimmune illnesses, cancer, and some other diseases. In this review, we summarize the data about anti-IDs that mimic the structural and functional properties of some bioregulators (autacoids, neurotransmitters, hormones, xenobiotics, and drugs) and evaluate their possible medical applications. The immune system is potentially able to reproduce or at least alter the effects of any biologically active endogenous or exogenous immunogenic agent via the anti-idiotypic principle, and probably regulates a broad spectrum of cell functions in the body, being a kind of universal remedy or immunacea, by analogy to the legendary ancient goddess of universal healing Panacea (Πανάκεια, Panakeia in Greek) in the treatment and prevention of diseases, possibly including non-infectious somatic and even hereditary ones. MDPI 2020-05-28 /pmc/articles/PMC7345059/ /pubmed/32481667 http://dx.doi.org/10.3390/antib9020019 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Stanova, Aliya K.
Ryabkova, Varvara A.
Tillib, Sergei V.
Utekhin, Vladimir J.
Churilov, Leonid P.
Shoenfeld, Yehuda
Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
title Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
title_full Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
title_fullStr Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
title_full_unstemmed Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
title_short Anti-Idiotypic Agonistic Antibodies: Candidates for the Role of Universal Remedy
title_sort anti-idiotypic agonistic antibodies: candidates for the role of universal remedy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345059/
https://www.ncbi.nlm.nih.gov/pubmed/32481667
http://dx.doi.org/10.3390/antib9020019
work_keys_str_mv AT stanovaaliyak antiidiotypicagonisticantibodiescandidatesfortheroleofuniversalremedy
AT ryabkovavarvaraa antiidiotypicagonisticantibodiescandidatesfortheroleofuniversalremedy
AT tillibsergeiv antiidiotypicagonisticantibodiescandidatesfortheroleofuniversalremedy
AT utekhinvladimirj antiidiotypicagonisticantibodiescandidatesfortheroleofuniversalremedy
AT churilovleonidp antiidiotypicagonisticantibodiescandidatesfortheroleofuniversalremedy
AT shoenfeldyehuda antiidiotypicagonisticantibodiescandidatesfortheroleofuniversalremedy